[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adult-congenital-heart-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adult-congenital-heart-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,49,78,107,149,177,203,226,247,270,290],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100589324","psychological-trauma-post-traumatic-stress-disorder-and-resilience-in-adults-with-congenital-heart-disease-100589324",false,"NCT06952933","Psychological Trauma, Post-Traumatic Stress Disorder, and Resilience in Adults With Congenital Heart Disease","PTSD in ACHD","Inclusion Criteria:\n\n* Congenital heart disease diagnosis, age \\>= 18 years\n* Enrolled in CHI registry\n* English proficiency for survey completion\n* Access to an internet connection. Can be via computer or handheld device.\n\nExclusion Criteria:\n\n* Any who opt out\n* Age \\\u003C 18 years\n* No diagnosis of congenital heart disease\n* Not enrolled in CHI registry\u002Funable to access Internet","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","3 Months","OBSERVATIONAL","The purpose of this study, entitled \"Psychological trauma, post-traumatic stress disorder, and resilience in adults with congenital heart disease in a large population sample\", is to evaluate for exposures during a lifetime with congenital heart disease that may be associated with higher likelihood of developing PTSD.\n\nPrimary aim:\n\n\\- Identify individual patient characteristics (medical, psychosocial, socioeconomic, etc.) that are associated with a diagnosis of PTSD.\n\nSecondary aims:\n\n* Calculate the prevalence of those meeting PTSD criteria in the ACHD population using the \"gold standard\" diagnostic clinician interview, while using the same data to validate a PTSD screening self-report survey in the ACHD population.\n* Determine the role of resilience in ACHD patients using a validated screening survey to assess its protective role toward PTSD.\n\nHypotheses:\n\n* There are certain exposures (e.g. post-surgical pain, ICU delirium, bullying due to CHD) that are associated with a higher incidence and odds of meeting PTSD criteria.\n* \"Gold standard\" diagnostic interviews will most accurately estimate the prevalence of PTSD in ACHD which has been overestimated on prior screening-based studies, although the scope of the problem is still great.\n* Patients with a higher resilience score will show an association with a lower risk of PTSD.",[25,26,27],"Adult Congenital Heart Disease","Congenital Heart Disease","PTSD",[29,30,31,32,33,34,35],"adult congenital heart disease","achd","congenital heart disease","pediatric cardiology","ptsd","post-traumatic stress disorder","resilience","RECRUITING","2026-03-23",{"date":39,"type":40},"2026-03-25","ACTUAL",{"date":42,"type":40},"2025-09-01",{"date":44,"type":20},"2026-08",{"name":46,"class":47},"Dartmouth-Hitchcock Medical Center","OTHER",3,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100629821","ai-enabled-frailty-risk-prediction-in-adult-congenital-heart-disease-100629821","NCT07479654","AI-Enabled Frailty Risk Prediction in Adult Congenital Heart Disease","Precision Risk Prediction of Symptom Clusters and Frailty With AI-Guided Emotion Detection: A Three-Year Study in Adults With Congenital Heart Disease","Inclusion Criteria:\n\n1. Adults aged 20 years or older.\n2. Diagnosed with congenital heart disease by a physician.\n3. Able to communicate in Mandarin or Taiwanese, with normal cognitive function.\n\nExclusion Criteria:\n\n1. Presence of other congenital anomalies.\n2. Currently hospitalized for acute decompensation, or having severe cognitive impairment or psychiatric symptoms that preclude completion of questionnaires.\n3. Pregnant individuals.","20 Years",{"count":58,"type":20},410,"INTERVENTIONAL",[61],"NA","The goal of this three-year mixed-methods observational study with an embedded randomized controlled trial is to develop and validate a frailty risk prediction model and evaluate an artificial intelligence-based voice emotion detection-guided counselling intervention in adults with congenital heart disease (ACHD).\n\nThe main questions it aims to answer are:\n\nAre symptom clusters associated with frailty and psychological outcomes in adults with congenital heart disease?\n\nCan symptom clusters and psychosocial factors be used to predict frailty risk over time in ACHD patients?\n\nDoes an AI-based voice emotion detection-guided counselling intervention improve psychological outcomes, fatigue, and quality of life among high-risk ACHD patients?\n\nResearchers will compare ACHD patients receiving AI-based voice emotion detection-guided counselling with those receiving usual care to determine whether the intervention reduces depression, anxiety, sleep disturbance, fatigue, and frailty risk, and improves grit and quality of life.\n\nParticipants will:\n\nComplete longitudinal assessments of symptom clusters, frailty, and psychological status at baseline and follow-up time points\n\nParticipate in qualitative interviews to explore lived experiences related to symptoms and frailty\n\nReceive AI-based voice emotion detection-guided counselling (intervention group only in Year 3)",[25,64,65,66,67],"Symptom Clusters","Frailty","Risk Prediction Model","Artificial Intelligence-Based Voice Emotion Detection","NOT_YET_RECRUITING","2026-03-15",{"date":71,"type":40},"2026-03-18",{"date":73,"type":20},"2026-03-01",{"date":75,"type":20},"2028-12-31",{"name":77,"class":47},"Mackay Memorial Hospital",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":16,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":89,"studyType":22,"phases":4,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100629632","heart-institute-biobank--registry-for-adult-congenital-heart-disease-and-related-disorders-100629632","NCT07477197","Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders","HIBR-ACHD","Inclusion Criteria:\n\n1. Any person ≥ 16 years-old suspected of having or diagnosed with congenital heart disease (CHD), other cardiovascular disease (CVD), pulmonary hypertension, connective tissue disease, or genetic syndrome\u002Fdiagnosis.\n2. Additionally, a cohort (Control group A) of control subjects will be enrolled, again ≥16 years-old, self-reported non-smokers without a known history of diabetes mellitus, myocardial infarction, stroke, heart failure, or chronic kidney disease. These controls will be either:\n\n   1. A family member or other person accompanying a patient to a clinical encounter; or,\n   2. A volunteer recruited via an advertisement; or,\n   3. Another person who volunteers to enroll in HIBR-ACHD.\n3. A cohort (Control group B) of comparison subjects who do not have CHD, but have a diagnosis of heart failure or pulmonary hypertension.\n\nExclusion Criteria:\n\n* Unable to provide informed consent\u002Fassent personally or via a legal guardian.\n* Considered unsafe to collect the biospecimen determined by either a clinical provider or an HIBR-ACHD investigator.\n* Overnight hospitalization for non-obstetric reason with discharge in the prior 30 days.",true,"16 Years",{"count":88,"type":20},5000,"10 Years","A repository of biospecimens and detailed phenotypic information collected longitudinally from adults with congenital heart disease and related conditions, with an aim to facilitate future research on biologic mechanisms of underlying disease, compensation and deterioration; biologic correlates of patient experience and functional status; associations between clinical characteristics and various biomarkers; and predictors of clinical outcomes.",[25,92,93,94],"Pulmonary Hypertension","Connective Tissue Disease","Other Cardiovascular Conditions",[96,25],"ACHD","2026-03-13",{"date":99,"type":40},"2026-03-17",{"date":101,"type":40},"2021-07-01",{"date":103,"type":20},"2050-01-01",{"name":105,"class":47},"Children's Hospital Medical Center, Cincinnati",1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":117,"studyType":22,"phases":4,"briefSummary":118,"conditions":119,"keywords":126,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":5},"100587722","adult-congenital-heart-disease-international-evaluation-of-the-effectiveness-of-sglt2i-registry-100587722","NCT06932081","Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry","Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i (ACHIEVE-SGLT2i) Registry","ACHIEVE-SGLT2i","Inclusion Criteria:\n\n* Congenital heart defect.\n* Age ≥ 18 years.\n* Initiated on treatment with an SGLT2i.\n\nExclusion Criteria:\n\n\\- No consent for data collection.",{"count":116,"type":20},400,"1 Year","This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.",[25,26,120,121,122,123,124,125],"Systemic Right Ventricle","Transposition of the Great Arteries","Congenitally Corrected Transposition of the Great Arteries","Fontan","Single Ventricle","Tetralogy of Fallot (TOF)",[29,96,31,127,128,129,130,131,132,133,134,135,136,123,137,138,139],"CHD","sodium-glucose cotransporter 2 inhibitors","SGLT2i","SGLT2","heart failure","HF","transposition of the great arteries","TGA","systemic right ventricle","sRV","single ventricle","tetralogy of fallot","ToF","2026-02-11",{"date":142,"type":40},"2026-02-13",{"date":144,"type":40},"2023-01-01",{"date":146,"type":20},"2027-12-31",{"name":148,"class":47},"Leiden University Medical Center",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":59,"phases":159,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":175,"locationsCount":4},"100620227","phase-4-effect-of-tirzepatide-on-cardiovascular-and-metabolic-parameters-in-obese-adult-patients-with-congenital-heart-disease-100620227","NCT07354880","Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease","TEACH","Inclusion Criteria:\n\n* Obese or overweight adult patients with congenital heart disease\n* BMI between 30 kg\u002Fm² and 40 kg\u002Fm²\n* Prior comprehensive non-pharmacological and non-surgical management of obesity, including a history of at least 12 months of intensive lifestyle intervention with a maximum weight reduction of less than 5%\n* Stable body weight within the three months preceding study enrollment (defined as weight fluctuations within 5%)\n* No prior pharmacological or surgical interventions for obesity\n* Euthyroid state\n* Eumenorrhea or oligomenorrhea\n* Ability to comprehend the study objectives and procedures\n* Willingness to provide informed consent and to comply with the study protocol, including the use of highly effective contraception during the study period, with signed consent and agreement provided in duplicate\n* Commitment to use highly reliable contraception and absence of plans for pregnancy within the 8 months following enrollment.\n\nExclusion Criteria:\n\n* Down syndrome\n* Type 2 diabetes\n* Severe heart failure (NYHA IV), EF of systemic or subpulmonary ventricle \\\u003C 30%, malignant arrhythmias, severe heart valve disease\n* Personal history of malignancy, personal or family history of medullary thyroid carcinoma\n* Personal history of pancreatitis or cholelithiasis\n* Personal history of acute coronary events or hemodynamically significant coronary artery disease\n* Current treatment with sympathomimetics or sympatholytic\n* Psychiatric disorders, personal history of depressive disorders or suicidal ideation\n* Pregnancy or lactation, postmenopausal, amenorrhea, reliance on natural contraception methods\n* Excessive alcohol consumption\n* Smoking","70 Years",{"count":158,"type":20},30,[160],"PHASE4","Several drugs have been shown effective in the treatment of obesity, with concomitant favourable cardiovascular effects. Today, there are no studies on novel anti-obesity drugs in patients with adult congenital heart disease (ACHD). Therefore, the investigators aim to study the effects of the anti-obesity drug tirzepatide (Munjaro) on cardiovascular and metabolic factors in obese patients with ACHD.\n\nIn a 24-week, randomized, open-label, placebo-controlled clinical trial the investigators will compare the effects of tirzepatide versus placebo in ACHD patients diagnosed with obesity. Patients will be randomized in a 1:1 ratio to either the intervention or placebo group. Participants will have monthly visits to monitor progress. At the beginning and end of the study, a full investigation protocol will be performed.",[163,25],"Obesity & Overweight",[165,29,166,167,168],"Obesity","tirzepatide","cardiovascular factors","metabolic factors","2026-01-18",{"date":171,"type":40},"2026-01-21",{"date":173,"type":20},"2026-01-20",{"date":146,"type":20},{"name":176,"class":47},"University Medical Centre Ljubljana",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":59,"phases":187,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":48},"100536071","phase-4-efficacy-of-sodium-glucose-transporter-inhibitor-sglt2i-in-adult-patients-with-congenital-heart-disease-100536071","NCT06260059","Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease","Efficacy of Sodium Glucose Transporter Inhibitor (SGLT2i) in Adult Patients With Congenital Heart Disease","EmpaCHD","Inclusion Criteria:\n\n* Diagnoses of Congenital Heart Disease\n* Age 18+\n* ACHD level of structural complexity II or III\n* Recent (\\\u003C6 months) decrease in systemic Ejection Fraction (confirmed by cardiac Echocardiogram, Computed Tomography or cMRI) to EF \\\u003C 60%\n* Recent decrease in systemic ejection fraction confirmed by cardiac Echo, CT or MRI by \\> 5% in the last 6 months or less.\n* Must be able to complete neurocognitive assessments on a handheld computer.\n\nExclusion Criteria:\n\n* Diagnosed with Diabetes\n* Contraindication to Jardiance\u002FEntresto or any heart failure medication (per guideline-directed therapy, 2022).\n* Previous therapy with Jardiance at \\\u003C4 weeks\n* Glomerular Filtration Rate \\\u003C20\n* Pregnancy, breastfeeding, or planning to become pregnant in the coming year\n* History of liver disease - including non-alcoholic fatty liver disease (NAFLD) and cirrhosis\n* History of inborn error(s) of metabolism (including but is not exclusive of Glycogen storage disease type 1)\n* Glucose-galactose malabsorption, familial hyperinsulinism, maple syrup urine disease,\n* Gaucher disease,\n* Tay-Sachs disease,\n* Mucolipidosis IV,\n* Niemann-Pick disease,\n* Type A mitochondrial disease,\n* Metabolic disorders related to glucose metabolism",{"count":186,"type":20},40,[160],"The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).",[25,190],"Heart Failure",[31,192,193],"reduced exercise capacity","decreased cardiac function","2025-10-02",{"date":196,"type":40},"2025-10-06",{"date":198,"type":40},"2024-09-17",{"date":200,"type":20},"2027-06-01",{"name":202,"class":47},"Anita Saraf",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":225,"locationsCount":106},"100590631","real-world-data-on-the-effects-of-cardiac-resynchronization-therapy-in-adult-patients-with-congenital-heart-disease-100590631","NCT06969924","Real-World Data on the Effects of Cardiac Resynchronization Therapy in Adult Patients With Congenital Heart Disease","RECORD-CHD","Inclusion Criteria:\n\n* ACHD patients who underwent CRT implantation\n\nExclusion Criteria:\n\n* Less than 18 years old on the moment of CRT implantation\n* Patient objection to the use of retrospective data",{"count":211,"type":20},100,"This study aims to evaluate the real-world effects of cardiac resynchronization therapy (CRT) in adult patients with congenital heart disease (ACHD). Specifically, it seeks to determine whether CRT improves clinical outcomes in this unique patient population and to identify factors associated with a favorable response to therapy.",[25],[215,216,96,217,218,132],"Adult congenital heart disease","Cardiac resynchronization therapy","CRT","Heart failure","2025-05-13",{"date":221,"type":40},"2025-05-14",{"date":223,"type":40},"2014-01-01",{"date":75,"type":20},{"name":148,"class":47},{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":233,"targetDuration":235,"studyType":22,"phases":4,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":106},"100575226","observational-cohort-study-of-adult-patients-with-congenital-heart-disease-100575226","NCT06769529","Observational Cohort Study of Adult Patients With Congenital Heart Disease","ACHD-BO","Inclusion Criteria:\n\n* Patients with congenital heart disease in natural history or previously undergoing palliative or corrective surgery in the time period after 14\u002F02\u002F2014\n* Obtaining informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Inability to obtain longitudinal data after the first follow-up performed at our Center.",{"count":234,"type":20},2000,"11 Years","The aim of this retrospective and prospective single-center observational study is to evaluate the correct management of adult patients with congenital heart diseas (ACHD), based on the experience of a reference center such as the Institute of Pediatric Cardiology at Policlinico Sant'Orsola Malpighi. The patients participating in this study will not be subjected to any procedures beyond normal daily clinical practice; likewise, the clinical variables that will be collected for the study are those that are commonly collected by the physician in daily clinical practice. This study therefore involves naturalistic observation of current clinical practice without the application of any kind of intervention.",[25],"2025-01-29",{"date":240,"type":40},"2025-01-31",{"date":242,"type":40},"2024-04-18",{"date":244,"type":20},"2025-05-01",{"name":246,"class":47},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":59,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":106},"100576372","search-for-noninvasive-markers-of-graft-injury-in-pediatric-and-adult-patients-with-congenital-heart-disease-undergoing-cardiac-transplantation-100576372","NCT06784440","Search for Noninvasive Markers of \"Graft Injury\" in Pediatric and Adult Patients With Congenital Heart Disease Undergoing Cardiac Transplantation","Inclusion Criteria:\n\n* Adult patients with congenital heart disease undergoing cardiac transplantation at our center or other centers, followed in follow-up at our center (Unit of Pediatric Cardiology and Developmental Age, IRCCS Azienda Ospedaliero-Universitaria di Bologna)\n* Pediatric patients undergoing cardiac transplantation at our center or other centers but followed in follow-up at our center\n* Obtaining informed consent from the adult patient or parent\u002Fguardian in case of minor\n\nExclusion Criteria:\n\n* Failure to obtain informed consent from the adult patient or parent\u002Fguardian in case of minor","44 Years",{"count":255,"type":20},20,[61],"This clinical tissue-based, drug-free, single-center, longitudinal study aims to validate a new diagnostic method, namely, to evaluate whether plasma levels of circulating donor free DNA in the recipient's blood (Dd-cfDNA: donor-derived cell free DNA), in patients undergoing orthotopic heart transplantation, can be predictive of the presence of acute myocardial rejection with the same sensitivity as immunohistochemical analysis on endomyocardial biopsy specimen, the current gold standard for the diagnosis of acute cell-mediated myocardial rejection, in a population consisting of pediatric patients and adult patients with congenital heart disease undergoing orthotopic heart transplantation.",[259,260,25,261],"Congenital Heart Disease (CHD)","Heart Transplant Patients","Pediatric Congenital Heart Disease","2025-01-14",{"date":264,"type":40},"2025-01-20",{"date":266,"type":40},"2023-03-08",{"date":268,"type":20},"2026-03-07",{"name":246,"class":47},{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":278,"targetDuration":280,"studyType":22,"phases":4,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":289,"locationsCount":106},"100575696","should-we-avoid-performing-invasive-coronary-angiography-before-cardiac-surgery-in-achd-patients-100575696","NCT06775639","Should we Avoid Performing Invasive Coronary Angiography Before Cardiac Surgery in ACHD Patients?","Should we Avoid Performing Invasive Coronary Angiography Before Cardiac Surgery in ACHD (Adult Congenital Heart Disease) Patients? The SPARE Observational Study","SPARE","Inclusion Criteria:\n\n* Adult congenital heart disease patient who is a candidate for cardiac surgery for correction of defect valve, or who performed the surgery after 01.01.2010\n* Clinical indication for preoperative ICA and CCT performed less than 12 months apart within 12 months of planned cardiac surgery\n* Age ≥ 18 years\n* Obtaining written informed consent\n\nExclusion Criteria:\n\n* Inability to perform ICA for any reason (e.g., poor vascular access or anatomical difficulty in reaching the coronary arteries)\n* Patient with severe renal failure on dialysis therapy\n* Patient with previous cerebri stroke",{"count":279,"type":20},80,"2 Days","The goal of this observational study is to compare two pre-operative methods, that is the Invasive Coronary Angiography (ICA), an actual standard diagnostic method, with the Coronary Computer Tomography (CCT) to undestand if the only CCT is sufficent to confirm the presence of a significative coronary disease and so to identify possible lesions in the coronary ematic circle, for example: stenosis and narrowing of coronary vessels. This observational study included people who have a congenital heart desease with indication of cardiac surgery and, why this disease, who had already performed these two diagnostic methods and\u002For who will perform them. The main question it aims to answer is: Should we avoid performing invasive coronary angiography (ICA) before cardiac surgery in people who have congenital heart desease (ACHD patients)?",[25],"2025-01-09",{"date":285,"type":40},"2025-01-15",{"date":287,"type":20},"2025-01-08",{"date":244,"type":20},{"name":246,"class":47},{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":106},"100571703","prognosis-in-adult-patients-with-congenital-heart-disease-100571703","NCT06723704","Prognosis in Adult Patients With Congenital Heart Disease","Prognosis in Adult Patients With Congenital Heart Disease: an Observational Study","PRO-ACHD","Inclusion Criteria:\n\n* Patients evaluated in our ACHD Outpatient Clinic between January 2014 and December 2026\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Patients without congenital heart disease confirmed during the first evaluation\n* Impossibility to retrieve information about the first clinical evaluation in our clinic from our electonic datasets\n* Follow up shorter than one-year\n* Refused consent to participate to the study.",{"count":299,"type":20},450,"This is a mono-center observational ambispective study in which adult patients with congenital heart disease evaluated at our institution will be enrolled.\n\nThe primary endopoint is to assess the clinical and echocardiographic predictors of adverse events during follow-up (death, arrhythmias, cardiac hospitalization).\n\nThe secondary endpoints are: 1) evaluation of the incidence of the singular components of the primary endpoint; 2) evaluation of the prognostic impact of acquired lesions, including valve disease not present at birth; 3) need for surgical\u002Fpercutaneous interventions during follow up.\n\nParticipants will be evaluated in the context of scheduled follow-up visits in our Outpatient ACHD Clinic. No interventions\u002Fdrug administration will be performed other than those required by standard clinical practice.",[25],[29,96,303,304,305],"prognosis","long-term","follow-up","2024-12-04",{"date":308,"type":40},"2024-12-09",{"date":310,"type":40},"2022-03-21",{"date":312,"type":20},"2026-12-31",{"name":314,"class":47},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]